Project Grant F30CA288018
Award Date
12/24/24
Completion Date
6/30/28
Dollars Obligated
$108K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor immunity,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $702,748 to Weill Medical College of Cornell University to conduct research on the role of neutrophils in anti-tumor immunity and immune-related adverse events associated with T cell-based cancer therapies. The key objectives are to: Characterize the gene pathways and tumor-derived factors that define functional subsets of anti-tumorigenic neutrophils, with the goal of...
This National Cancer Institute (CFDA 93.396 Cancer Biology Research) Project Grant award to the Icahn School of Medicine at Mount Sinai in the amount of $560,297 will fund a 5-year research project to functionally characterize "oncofetal stem cells" in colorectal cancer (CRC). The project aims to: Generate reporters to track the dynamics of CRC stem cell populations, including oncofetal stem cells and LGR5+ cancer stem cells. The researchers will then use these reporters coupled to a...
This $205,700 Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research supports research aimed at addressing the problem of rapid resistance to targeted therapies in colorectal cancer. The key objectives are to evaluate how intrinsic tumor features modulate the development of resistance, and to test a novel combination therapy approach of DNA repair inhibition and targeted therapy to prevent resistance...
This $640,583 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to enhance the efficacy of immunotherapy against metastatic colorectal cancer (MCRC). The primary goal is to activate the PPARD-CPT1A axis in CD8+ T cells to boost their metabolic fitness and anti-tumor immunity within the immunosuppressive MCRC tumor microenvironment. The project, awarded to Cold Spring Harbor Laboratory, involves three synergistic research...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Weill Medical College of Cornell University provides $237,724.00 in funding from March 12, 2025 to February 28, 2027 to investigate the role of p53 mutational status as a key determinant of radiation therapy's ability to induce cancer cell-intrinsic interferon-I pathway activation and in situ immunization. The research will utilize various p53-isogenic mouse and human cancer cell lines as...
This $160,642 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research conducted by Weill Medical College of Cornell University to characterize the role of oncogenic NRAS mutations in isocitrate dehydrogenase (IDH) mutant acute myeloid leukemia (AML). The research aims to elucidate how NRAS mutations modulate the leukemogenesis and therapeutic responsiveness of IDH mutant AML, with a focus on understanding the mechanism by which NRAS...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program provides $154,642 from March 1, 2025 to February 28, 2027 to the Sloan-Kettering Institute for Cancer Research, a prominent non-profit cancer research organization. The objectives of the grant are to systematically elucidate the evolving immunopeptidome from normal colon, primary tumor, and metastatic lesion patient-derived organoids through mass spectrometry to identify conserved...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $606,839 to Weill Medical College of Cornell University to conduct research on the role of gut microbiota amino acid metabolism in cancer. The key objectives are to: 1) Identify microbes and their metabolic genes that deplete intestinal amino acids and evaluate how this affects the tumor microenvironment and cancer progression; 2) Elucidate the molecular mechanisms by which...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to explore the role of aberrant splicing in cancer cell heterogeneity and its potential as a target for cancer immunotherapies. The $122,032 award, with a performance period from February 1, 2025 to January 31, 2027, is being provided to Weill Medical College of Cornell University, a prominent academic medical institution. The research aims to achieve three objectives: 1)...